Future Developments: UK Radiopharmaceuticals Market Technology
Looking toward 2030, the frontier of UK nuclear medicine lies in "Alpha-Therapy" and personalized dosimetry. The UK Radiopharmaceuticals Market Developments are currently focused on software that can calculate the exact radiation dose delivered to a tumor in real-time, allowing for a truly bespoke treatment plan for every patient. This "Targeted Alpha Therapy" (TAT) is expected to be a...
0 Reacties 0 aandelen 107 Views 0 voorbeeld